Gilenia's Risk Management Should Key On Initial Doctor Visit, Cmte. Says

Novartis' Risk Evaluation and Mitigation Strategy for Gilenia (fingolimod) may need to include more explicit testing requirements instead of just the physician and patient education programs that the firm has proposed